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Background: Multiple sclerosis is a chronic neurological condition usually starting in early adulthood and regularly
leading to severe disability. Immunotherapy options are growing in number and complexity, while costs of treatments
are high and adherence rates remain low. Therefore, treatment decision-making has become more complex for patients.
Structured decision coaching, based on the principles of evidence-based patient information and shared decision-making,
has the potential to facilitate participation of individuals in the decision-making process.
This cluster randomised controlled trial follows the assumption that decision coaching by trained nurses, using
evidence-based patient information and preference elicitation, will facilitate informed choices and induce higher decision
quality, as well as better decisional adherence.
Methods/Design: The decision coaching programme will be evaluated through an evaluator-blinded superiority cluster
randomised controlled trial, including 300 patients with suspected or definite relapsing-remitting multiple sclerosis, facing
an immunotherapy decision. The clusters are 12 multiple sclerosis outpatient clinics in Germany. Further, the trial will be
accompanied by a mixed-methods process evaluation and a cost-effectiveness study.
Nurses in the intervention group will be trained in shared decision-making, coaching, and evidence-based patient
information principles. Patients who meet the inclusion criteria will receive decision coaching (intervention group) with
up to three face-to-face coaching sessions with a trained nurse (decision coach) or counselling as usual (control group).
Patients in both groups will be given access to an evidence-based online information tool.
The primary outcome is ‘informed choice’ after six months, assessed with the multi-dimensional measure of informed
choice including the sub-dimensions risk knowledge (questionnaire), attitude concerning immunotherapy (questionnaire),
and immunotherapy uptake (telephone survey). Secondary outcomes include decisional conflict, adherence to
immunotherapy decisions, autonomy preference, planned behaviour, coping self-efficacy, and perceived involvement
in coaching and decisional encounters. Safety outcomes are comprised of anxiety and depression and disease-specific
quality of life.
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Discussion: This trial will assess the effectiveness of a new model of patient decision support concerning
MS-immunotherapy options. The delegation of treatment information provision from physicians to trained nurses
bears the potential to change current doctor-focused practice in Germany.
Trial registration: Current Controlled Trials (identifier: ISRCTN37929939), May 27, 2014.
Keywords: Multiple sclerosis, Coaching, Shared decision-making, Cluster randomised controlled trial, Patient information,
Nurses, Self-management, Evidence-based medicineBackground
Multiple sclerosis (MS) is a chronic, inflammatory,
autoimmune disorder, which is characterised by destruc-
tion of myelin in the central nervous system. The disease
affects mainly young adults, with an average age of onset
of around 30 years [1,2].
Around 2,000,000 people worldwide are affected with
MS and at least 120,000 people in Germany have MS
[3]. Further, recent insurance company based numbers
have estimated there to be around 180,000 affected people
in Germany [4]. There are between 3,000 to 5,000 new
cases every year in Germany (four to six per 100,000).
Due to the long course of this disease and resulting
severe disabilities, MS is of major health economic
relevance [5]. Annual costs per patient in Europe are
estimated at €18,000 for mild MS (Expanded Disability
Status Scale (EDSS) <4.0), €36,500 for moderate MS
(EDSS 4.0 to 6.5) and €62,000 for severe MS (EDSS >7.0)
[6]. Total societal costs in Germany have been estimated
at around €4,000,000,000 in 2001 [3].
Due to many uncertainties such as the possibility of a
benign variant of MS [7,8], and unclear long-term benefits
of treatments, some of them with life-threatening risks
[9], immunotherapy decisions are not straightforward. In
addition, recent studies have shown non-adherence rates
of up to 50% within the first two years of treatment [10].
Thus, immunotherapy decision-making and decisional
adherence are of high personal and societal relevance.
A shared decision-making (SDM) approach is currently
regarded as the ideal approach in medical decision-making,
based on the ethical principle of patient autonomy and on
patient preferences [11]. A prerequisite of SDM is the
availability of balanced and understandable information
emphasising the crucial position of evidence-based patient
information (EBPI) in this process [11]. A second aspect
of SDM is self-reflection on values and preferences, which
might substantially differ between patients and physicians
[12]. This ideal concept of informed SDM is confronted
with the current situation of medical care in Germany and
other European countries, characterised by an increased
burden of work for increasingly fewer physicians [13].
During recent years, so-called MS specialist nurses
have been established, partially with the support of pharma-
ceutical companies for coaching patients on injectabletreatments [14]. Although in some countries nurses already
have active roles [15], there has been no widespread,
systematic integration of MS nurses into immunotherapy
decision-making processes based on EBPI. Coaching,
provided in a structured manner and according to the
principles of EBPI, can facilitate participation of individuals
in the decision-making process. In this trial the following
coaching definition of Stacey et al. [16] is applied:
‘Coaching is defined as the provision of support by a
trained individual (either in person or remotely - for
example by telephone or internet), who is supportive
but non-directive, for a patient or family facing a decision’
[16]. Further, decision coaching is determined by the
inclusion of SDM and EBPI components, as for example
the assessment of patients’ decision-making needs,
provision of information on benefits and harms of each
option, and the facilitation and monitoring of the
decision-making progress [16].
In a recent systematic review [17], decision coaching
provided along patient decision aids has been summarised
based on trials reviewed in a Cochrane review [18]. The
systematic review could not show a benefit regarding
knowledge improvement compared to provision of patient
decision aids only. For other outcomes, the trials pro-
duced diverse results, yet no negative effects have been
demonstrated. Due to these findings and the limited num-
ber of trials, the authors concluded that further research
in this area is needed [17]. However, in those trials where
coaching has been provided by nurses, results are in
general more promising [19-21].
We assume that beyond thoroughly developed decision
support technologies and advanced communication
concepts, structural change in clinical decision-making is
essential for successful implementation of patient in-
volvement into clinical practice. Therefore, this trial
aims at clarifying the possible gains of, and also barriers
to, giving MS nurses a crucial role in immunotherapy
decision-making processes. The nurse decision coach
model has been developed to redistribute health profes-
sionals’ tasks in supporting patients’ decision-making pro-
cesses [22]. Here, the physician encounter is supplemented
by the provision of an evidence-based online patient in-
formation tool (DECIMS-Wiki) and up to three decision
coaching sessions with specialist MS nurses (decision
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tion, to clarify patients’ own values, and to identify per-
sonal barriers in the decision-making process before a
decision is made. By this stepwise structured and indivi-
dualised process, we expect patients to be able to deeper
elaborate their own decisions and to more actively partici-
pate in decision processes. Clarification of patients’ own
values, identification of barriers, evidence-based informa-
tion, and participation in decision processes are prerequi-
sites for patients in order to make informed choices and
to achieve high decision quality.
This protocol has been developed and structured
following the recommendations of the Standard Protocol
Items: Recommendations for Interventional Trials (SPIRIT)
2013 statement for clinical trial protocols [23]. Please see
Additional file 1 for the complete SPIRIT checklist.
Further, the Consolidated Standards of Reporting Trials
(CONSORT) extensions for cluster randomised trials and
for randomised controlled trials of non-pharmacologic
treatments have been considered and will be used for
reporting study results [24,25].
A recent Cochrane review showed that decision aids
[26] in health treatment enhance accurate expectations
and increase patient involvement. Also patient-physician
communication is positively influenced if values are
explicitly clarified. However, effects on decisional adherence
and health outcomes remain inconsistent. In another
Cochrane review [27] on interventions for health profes-
sionals to enhance SDM, all three trials out of 39 trials
using a nurse-based educative intervention showed changes
in consultations [28] and on patient relevant outcomes
[29,30], stressing the relevance of this approach. In
addition, our own Cochrane review on information
provision interventions in MS identified 10 randomised
controlled trials with heterogeneous approaches and
inconsistent results [31].
Since 2001, we have studied EBPI and SDM in MS
and conducted four controlled trials [32]. All interven-
tions were based on the concept that more patient
involvement through carefully developed information
leads to a greater sense of control and empowers
patients for disease-specific self-management especially
regarding treatment decision making. While epidemio-
logical studies in MS have consistently shown that object-
ive and perceived stress is a relevant relapse risk factor
[33], altered psychological factors might even impact on
the overall disease process [34]. Our first randomised
controlled trial clearly showed altered health behaviour in
MS relapse management after a four-hour educational
intervention in a cohort of 150 MS patients followed up on
for two years [35]. Interestingly, trained patients had less
relapses. On the other hand, a printed EBPI on immuno-
therapy alone was not sufficient to alter decision-making
processes in another trial [36].Other groups have engaged in the evaluation of
patients’ attitudes and risk behaviours as well as in
the effects of information provision (for review see
Giovannoni and Rhoades [37]). However, decision-making
about, and adherence to, immunotherapy with the aim of
an individualised treatment in MS remains a highly
complex topic.
Recently, we finished a multicentre study with 192
patients with early MS comparing group education to
a stress management intervention [38]. The intervention
significantly improved relevant risk knowledge and
informed choice. The same applies to another recently
terminated study addressing MS patients in rehabilitation
clinics offering an immunotherapy group education
programme [39]. In both trials, informed choices signifi-
cantly increased in the intervention group (IG), but no
effects on therapy decision-making or health outcomes
were found.
In summary, results for EBPI and decision support
indicate that it might not be sufficient to solely provide
information and/or decision aids. Apparently, patients
need time and support to reflect on the information and
discuss options. In case of more complex decisions, for
example on immunotherapy, the formerly applied
approaches seem to not be sufficient, and individual
decision support might be helpful in supplementing
physician consultations in order to achieve successful
informed SDM. In addition, group interventions are not
tailored to the individual treatment decision setting and can
therefore not account for differences in decision-making
priorities or individual information processing.
Here, specialist MS nurses seem the ideal candidates to
act as decision coaches, a concept successfully administered
in other diseases [17]. Up to now only one controlled study
addressed the impact of MS nurse counselling, showing
beneficial effects in sexual quality of life [40].
Aims and objectives
We hypothesise that structural changes in immunotherapy
decision-making, including redistribution of tasks between
specialist nurses (decision coaches) and physicians, will
enhance elaborated decisions and improve healthcare
management in MS. First, the intervention will empower
patients to make more informed choices, tailored to their
preferences and values. Second, decisional conflict will be
lower compared to controls, and decisional adherence
will be maintained. Third, decisional encounters will
demonstrate more SDM. Finally, self-efficacy and coping
competences will be enhanced.
Methods/Design
The DEcision Coaching In persons with relapsing-
remitting Multiple Sclerosis (DECIMS) trial will be carried
out as a superiority cluster randomised controlled trial.
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design, only outcome assessment can be blinded.
A cluster design is adequate as the intervention is
delivered to centres, specifically the nurses; therefore
centres have to be the unit of allocation. Thus, con-
tamination between nurses and patients of differently
treated groups based on a randomisation within the
centre is avoided. Moreover, it is possible to induce and
observe possible structural changes in the participating
MS-outpatient clinics.
Following the Medical Research Council guidance for
the development and evaluation of complex interven-
tions [41], the intervention was pre-tested with regard
to feasibility and is currently piloted in two centres
(St Josef-Hospital Bochum and University Medical
Center Hamburg-Eppendorf ). Furthermore, the main
study will be accompanied by a process evaluation and an
economic evaluation.
Study setting
The study will be conducted in different neurological out-
patient clinics throughout Germany. At present, 14 centres
participate in the DECIMS trial (see Additional file 2 for
details). The two study sites participating in the feasibility
and pilot trial (St Josef-Hospital Bochum and University
Medical Center Hamburg-Eppendorf) will not participate
in the main study.
Eligibility criteria
Neurological outpatient clinics in German hospitals
which have a specialisation in MS are eligible to participate.
Nurses are eligible if they specialise in the field of MS and
are currently employed at the participating centres.
Specialisation is defined as special qualifications and/or
long-standing professional experience in patients with MS.
Patient inclusion criteria
Patients older than 18 years with possible MS, defined
by a typical clinical syndrome and at least one MRI
lesion and/or positive oligoclonal bands [42]; and
patients with relapsing-remitting MS (RRMS), according
to the McDonald criteria [43], will be included. To
achieve a homogeneous sample, only patients deciding on
starting, stopping, or changing first-line MS immunotherapy
therapy (glatiramer acetate, interferon-beta preparations,
dimethyl fumarate or teriflunomide) will be included. This
will lead to inclusion of recently diagnosed MS patients as
well as patients under treatment, considering switching
from an injectable to an oral drug. Although patients
with very early or established RRMS under treatment
might differ considerably with respect to attitudes, disease
experience, and disability, as well as availability of thera-
peutic options, these factors can be controlled for and any
effect of disease stage can be investigated. Likewise, thesetwo scenarios are highly representative for daily routine
and practice.
The study will use the internet for information provision
and data collection; therefore only patients with access to
the internet will be included.
Patient exclusion criteria
Patients with secondary-progressive MS, primary-progressive
MS, or any suspected central nervous system disease
other than MS will be excluded. Furthermore, patients
who are considered non-responders to a first-line
treatment and who are facing a decision on escalation
immunotherapy therapy (such as natalizumab, fingolimod,
or alemtuzumab) or symptomatic therapy will be excluded.
Also, severe cognitive deficit or major psychiatric illness
affecting information uptake are exclusion criteria. In
addition, patients who are related to medical personnel




The ‘decision coach programme’ has been developed
according to the Medical Research Council’s framework
for developing and evaluating complex interventions [41].
Considering the SDM communication concept [44], nurses
specialising in MS will take part in a training course to
acquire relevant skills to perform immunotherapy decision
coaching. Afterwards, they will conduct the study interven-
tion, which consists of up to three decision coaching ses-
sions per patient. As part of the intervention, a web-based
information tool, the DECIMS-Wiki, moderation cards,
and a patient workbook have been developed to pro-
vide information and to give guidance throughout the
decision-making process (see Figure 1).
The DECIMS-Wiki has been developed based on litera-
ture searches and an update of available brochure-based
information materials from previous studies [45]. The tool
was drafted by the research group at the study centre in
Hamburg and will be continuously revised in cooperation
with all participating study centres. In addition, each
patient will be provided with a patient workbook, which is
targeted to the specific kind of decision to be made
(first treatment or switchers). The decision nurses are
instructed to organise the coaching process considering six
subsequent topics to be discussed in a decision-making
process [46]. The six steps of an SDM-process are:
1. to review the problem requiring a decision-making
process;
2. key message: decisions cannot be made based on
evidence alone. It is the patient who needs to decide;
3. information about pros and cons of each option
(including no immunotherapy);
Figure 1 The DEcision Coaching In persons with relapsing-remitting Multiple Sclerosis (DECIMS) trial programme.
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5. decision (progress in decision-making, deferment is
a possible decision); and
6. arrangements.
The moderation cards and the patient workbook are
structured according to the above described six SDM
steps. Further, the moderation cards guide the inclusion
and connection of the DECIMS-Wiki and the patient
workbook into the coaching process.
The curriculum of the training programme is based
on previous expertise in the training of consumer
representatives [47]. Moreover, train-the-trainer expertise
from a previous programme was used [48]. The training
focuses basic skills in SDM, including EBPI and coaching,
using methods established in physician communication
trainings [49,50]. The training includes further guidance
on using the DECIMS-Wiki and insight into the use,
interpretation, and impact of findings on magnetic
resonance imaging (MRI) scans.
After randomisation, nurses in the intervention
clusters will receive special training. All nurses will
receive the same training provided by the same research
team. The training consists of provision of preparatory
materials and tasks, a training course (three days, 16 hours
in total), and a structured feedback (via telephone)
concerning coaching performance in practice after the
training course. Knowledge gain of the nurses will be eval-
uated through questionnaires (before and after training).
Up to six coaching sessions per decision coach will be
video-recorded shortly after the training to give structured
feedback on coaching performance. The videos will beevaluated independently by two researchers who will
use standardised forms to assess the quality of the
coaching session (in terms of SDM, EBPI, and coaching
competencies). When nurses, do not implement important
aspects which ensure a standardised delivery of the
intervention despite receiving this feedback, they will
be excluded from the study. Those aspects are:
1. no coaching according to the SDM criteria,
2. no use of the DECIMS-Wiki during the coaching,
3. not able to explain the bar charts on treatment
effects to participants,
4. no appropriate use of the moderation cards or their
contents during the coaching.
However, before a nurse will be excluded from the study,
efforts will be taken to communicate that information
(for example through extra training).
Eligible patients will receive their first coaching session
with the decision coach within two weeks after inclusion
with up to three coaching sessions per patient. Periods
between sessions should not exceed two weeks. A single
coaching session will last up to one and a half hour.
Patients and decision coaches (nurses) will evaluate
the coaching sessions via web-based questionnaires.
Additionally, decision coaches will keep a logbook to
document each coaching session.
Patients will be given access to the DECIMS-Wiki to
prepare for coaching sessions, to gain further relevant
knowledge, and to be able to reflect upon options
between coaching sessions. After the final coaching
session, patients will see a physician within two weeks to
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individual patients more than one medical encounter
will be necessary in order to make a decision. A total
of 40 physician-patient encounters will be audiotaped
in four centres in order to measure possible changes
in the physician-patient communication (for detailed
information see process evaluation).
In addition, physicians in both groups will receive an
information package on SDM. The package consists of
the following information:
1. A letter, including information about the study, the
SDM concept, and the request to follow the SDM
concept during the study.
2. A link to a video (password protected), which shows
a physician-patient conversation according to the
SDM concept.
3. An article, which provides information about SDM
in the field of neurology [51].
This information will be handed out to all participating
physicians in the IG as well as in the control group (CG),
since it is intended to assess the effects of the decision
coaching intervention using trained nurses alone.Control group
The CG will be given access to the evidence-based online
patient information-tool (DECIMS-Wiki), which will also
be used in the IG, including an information sheet on how
to use it, and otherwise receive care as usual.
Offering both groups access to evidence-based informa-
tion will allow for a better estimate whether possible dif-
ferences between groups can be attributed to nurse-led
decision coaching. For the same reason, physicians in the
CG also receive the SDM package.Criteria for discontinuation
Adverse events
Our previous work has shown that even complex infor-
mation about MS treatment evidence is appreciated by
patients [32]. Handing over information provision from
physicians to nurses might induce concerns among MS
patients. However, the framing of the intervention is as
‘preparation for a medical encounter’, therefore, we do
not believe that patients perceive the intervention as
a reduction of physician attention. The process is
individualised to the decision pace of individual patients,
allowing for individual decision-making processes. To
account for possible adverse events, we will continuously
monitor satisfaction with the process, which will be also
communicated to the Data and Safety Monitoring Board
(DSMB). We do not foresee any other harm of the
intervention.Patient withdrawal
Patients in both groups can quit the study at any time
point. Patients who withdraw from the study are asked
whether they agree to continue to fill in a limited set of
questionnaires related to the primary study outcome.
Physician encounters
It is aimed that patients do not see a neurologist during
the coaching stage. However, there are situations
where patients have to or want to see a neurologist
(for example, for relapse management). In these cases,
neurologists in the participating outpatient clinics and
practises are asked whenever possible not to discuss
immunotherapy options. Still, this might not always
be appropriate and some patients might also consult
a practice-based neurologist. Any physician encounter
will be documented.
Strategies to improve adherence
Decision coaches
All decision coaches will receive a study coach folder
including all relevant documents of the training, the
patient workbooks, moderation cards, and further material
on communication and coaching.
Coaching fidelity will be secured through different
measures: first, an interactive three-day training course
in Hamburg; and second, video feedback of two coaching
patients per nurse in the respective centre. Also, they will
be contacted regularly (monthly during the first three
months and every two to three months afterwards) to
ensure quality standards of coaching sessions and support
the decision coaches. Calls will consist of open and closed
questions and decision coaches will have the opportunity
to come up with their own aspects (as for example
questions concerning coaching procedures or the
DECIMS-Wiki). Furthermore, we aim to hold three to
four telephone conferences per year with participating
nurses from the IG. This will provide an opportunity
for the nurses to connect and share experiences, for
example to discuss difficult coaching situations.
Logbook
Decision coaches are further asked to use an online
logbook for each participant to support a standardised
delivery of the intervention.
Coaching sessions
Moderation cards will be provided to decision coaches
to ensure that the key components of the intervention
are delivered to the patients. This adds to the patient
workbook, which also provides guidance through the
SDM steps. Coaches might prepare sessions by looking
into the coaching cards. In each coaching session it is
aimed that the DECIMS-Wiki, the moderation cards,
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book and the moderation cards do serve as structuring aids
for the encounters.Strategies to facilitate the utilisation of the DECIMS-Wiki
Decision coaches will be informed about the DECIMS-Wiki
and use the tool during the training course, and the
DECIMS-Wiki will be addressed during telephone calls and
in the logbook. Beyond that, decision coaches will be
informed when the platform has been updated.Patients
If patients miss an appointment, they will be contacted
by the decision coach to arrange a new appointment.
Patients will be contacted by email by a member of
the coordinating centre in Hamburg when it is time
to fill in a form, and will be asked to complete the
questionnaires within a specified time period. Patients
who miss the completion will again be reminded by
email and telephone. When appropriate, patients willTable 1 Major endpoints CRCT
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EDSS X
SDMT X














t1 = after last decision coaching; t2 = directly after final physician decision encounte
physician encounter; t5 = six months after final physician encounter. CPS: Control Pr
EDSS: Expanded Disability Status Scale; HADS: Hospital Anxiety and Depression Scal
relationship trust scale; MAPPIN’SDM: Multifocal Approach to Sharing in Shared Decisio
Sclerosis; PBMS: Planned Behaviour in MS Scale; SDMT: Symbol Digital Modalities Test.be asked to fill in a questionnaire in the outpatient
clinic directly after an encounter.
Decision coaches will inform patients about the
DECIMS-Wiki and use the tool during the first coaching
sessions reminding patients to use it between sessions.
All patients will receive a personal password for the
DECIMS-Wiki and an information leaflet about the tool.
Relevant concomitant care
Relapse management
In case of deterioration, for example a relapse during
the coaching stage, the participant is free to consult a
specialist and receive appropriate treatment.
Outcomes
For a list of the major endpoints of the DECIMS trial,
see Table 1.
Primary outcome
We have previously applied the multi-dimensional measure
of informed choice in two controlled trials [52]. Here,Post-allocation





X (nurse) X (physician and patient)








r; t3 = two weeks after final physician encounter; t4 = three months after final
eference Scale; CSES: Coping self-efficacy scale; DCS: Decisional Conflict Scale;
e; HAQUAMS: Hamburg Quality of Life in MS Scale; HCR trust scale: Health care
n Making; MMIC: Multi-dimensional measure of informed choice; MS: Multiple
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bining three dichotomous measures: risk knowledge,
attitude, and therapy uptake. Informed choice encompasses
adequate risk knowledge, with either uptake or non-uptake
of immunotherapy, and a corresponding (congruent)
positive or negative attitude. Attitude will be assessed using
a single question directly after the final physician encoun-
ter. Uptake will be evaluated from the patient after six
months. Risk knowledge will be measured using a previ-
ously developed and adapted questionnaire 14 days, and
three and six months after the last physician encounter
[53]. As applied in a previous trial, the cut off for adequate
risk knowledge will be defined a priori as the value that
30% of all patients with highest scores reach at baseline. In
addition, risk knowledge will be analysed as a continuous
variable to enable comparability with other studies. Earlier
trials have shown that patients who meet the primary
endpoint more often realise their preferences [38,39].
Secondary outcomes
The Decisional Conflict Scale ((DCS) [54]) has been
used in numerous decision support interventions and is
regarded as a tool to monitor comfort with the decision
process. Here, a dyadic DCS [55] (patient - decision coach
and patient - physician) will be applied as key secondary
endpoint after the last coaching session (IG) and after the
final physician encounter (for both the IG and CG).
Further tools will be used to monitor decisional
processes assessing autonomy preferences (Control
Preference Scale (CPS) [56]), behavioural beliefs, and
self-efficacy (Planned Behaviour in MS Scale (PBMS) [57]).
Coping and self-efficacy will be assessed by application
of the recently validated Coping Self-efficacy Scale
(unpublished data Pöttgen J, Mohr DM, Ziegler K,
Gold SM, Heesen C) based on Chesney et al. [58]).
Perceived involvement in coaching and decisional encoun-
ters from patients’ as well as physicians’ and nurses’
perspectives will be evaluated with the Multifocal
Approach to Sharing in Shared Decision Making
(MAPPIN’SDM) evaluation [59]; applying a newly
developed short version. We will assess participants’
trust in nurses and physicians [60].
Decisional adherence (including the decision against
immunotherapy) and acceptance of the intervention
will be assessed from patients using a standardised
questionnaire at three and six months after the last
physician encounter (for both the IG and CG). Finally,
duration of decision coaching and physician encounters
will be documented.
Tertiary outcomes (control and safety parameters)
As control parameters we will use measures for anxiety and
depression using the Hospital Anxiety and Depression Scale
((HADS) [61]), and disease-specific quality of life using theHamburg Quality of Life in MS Scale ((HAQUAMS) [62]).
Moreover, standard disease-monitoring parameters will be
obtained; relapses and disability as measured by Expanded
Disability Status Scale ((EDSS) [63]) and the Symbol Digital
Modalities Test ((SDMT) [64]) for cognition. Occurrence
of relapses will be evaluated at baseline, 14 days, and three
and six months after the last physician encounter (for both
the IG and CG) using a standardised questionnaire.
Health economic outcomes
Data to perform health economic analyses will be
assessed with an adapted tool used in a previous trial
[35]. Patients will be asked to consent for collection of
health insurance data for the study period.
Focus will be the rate of patients initiating MS immuno-
therapy as well as relapse treatment prescription (including
route of administration). Further, number of MS-related
visits to neurologists and general physicians, number of
MRI scans, missed days at work, and hospital stays will be
evaluated.
Participant timeline
For a description of the flow of the DECIMS trial see
Figure 2.
CRCT: cluster randomised controlled trial; DCS:
Decisional Conflict Scale; MAPPIN'SDM: Multifocal
Approach to Sharing in Shared Decision Making; MMIC:
Multi-dimensional measure of informed choice RRMS:
relapsing-remitting multiple sclerosis
Screening visit
As it is not possible to coach all suitable patients in
every participating centre, not all potentially eligible
patients will be included. To avoid selection bias, possible
recruitment days will be randomly determined by a statisti-
cian for those centres, and an independent person will call
the study sites weekly to inform them about the recruit-
ment day(s).
Nurses (for both the IG and CG) will create a list on
all recruitment days, recording all MS patients who
attend the outpatient clinic that day. Potentially eligible
patients will be identified using a screening form (form one)
during an appointment. Screening form one has to be filled
in for every patient. Therefore, reasons why patients are not
suitable will be documented as well. When patients seem to
be suitable for the study, they will receive information about
the study from the physician or from a nurse. For diagnostic
cases in which an early treatment will be discussed,
physicians will invite patients after having communicated
diagnostic test findings. In the case of treatment switchers,
the encounter is stopped before counselling about the
possible immunotherapy options will take place. Physicians
have to fill in a second screening form, including the study
inclusion criteria, for all patients who seem to be suitable
Figure 2 DEcision Coaching In persons with relapsing-remitting Multiple Sclerosis (DECIMS) trial flow.
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patients fulfilling the inclusion criteria after they have had
enough time to read the study information sheet and ask
questions. The encounter will be stopped when informed
consent is given, and patients will be invited to fill-in
baseline data via an online questionnaire database and
will receive an access code to the DECIMS-Wiki after
the completion of baseline questionnaires. Depending
on the cluster’s group allocation, patients will receive
a new appointment with the physician or an appointment
with the decision coach. Suitable patients, who are not
willing to participate in the study, will be asked for the
reason (screening form two).
Baseline data and allocation
After information about group allocation, patients in
the CG will receive an information sheet about the
DECIMS-Wiki from a nurse, will receive usual care,
and a decisional encounter with the physician will be
scheduled. In the IG, apart from information about
access to the DECIMS-Wiki, an appointment for a
first encounter with the decision coach will be scheduled
within 14 days. After inclusion and the completion of
baseline questionnaires, patients will receive an elec-
tronic access code to the DECIMS-Wiki, which is
linked to the information technology platform of the
Krankheitsbezogenes Kompetenznetz Multiple Sklerose
((KKNMS) Competence Network Multiple Sclerosis).
Further appointments will be planned at the end of
each encounter, which could be up to two more with
the decision coach and up to two with a physician.
Encounters and web-based visits
After the last encounter with the decision coach, prompt
feedback from patients will be collected at the centre by
web-based questionnaires. After up to three meetings
with the decision coach (visits one to three), up to two
decisional encounters with a physician will take place
within four weeks. Decision coach encounters will be
videotaped and sent to the Hamburg study centre for
analysis by the research group.
Patients will be followed up on using web-based ques-
tionnaires within 14 days, after the final encounter with
the physician (web-based visit), after three months
(web-based visit), and after six months (web-based
visit and standardised telephone interview).
Additional visits
At least three randomly selected patients from each
intervention cluster will be contacted after the follow-up
period and asked to take part in an additional interview,
which will be conducted in the context of the accompany-
ing process evaluation (for details see process evaluation).
Furthermore, when additional funding is provided, patientswill be contacted via telephone by the study centre to assess
their current treatment status after 12 and 24 months.
Sample size
The primary endpoint of the DECIMS trial is informed
choice, that is, a fitting of good knowledge, a given
attitude, and the corresponding uptake. Each of these
three dimensions will get a dichotomous rating of ‘yes’ or
‘no’. Based on data from prior studies [35,36], we assume
that after the intervention, 60% of patients in the IG will
show ‘adequate’ knowledge compared to 40% in the CG.
Adequate knowledge is defined as the number of ques-
tions correctly answered by 30% of patients at baseline,
which was also applied in previous work. We assume that
in the IG group about 80% of attitudes and decisions are
congruent, compared to 70% in the CG. Therefore, we
expect 48% of IG patients to make informed decisions
compared to 28% of patients in the CG. In order to detect
this difference with a power of 90% and a significance level
of alpha = 0.05, 12 clusters with 23 patients per cluster
will be needed, assuming an intra-cluster correlation
coefficient of 0.0045, which is a conservative estimate
based on data from our previous trial [38].
Assuming a dropout rate of 10%, 25 participants per
centre will be needed, accounting for a total of 300
participants in 12 clusters. In all our previous trials
on EBPI, loss to follow-up was less than 10%. Therefore,
10% seems a realistic and conservative assumption.
Recruitment
Contact persons of different MS clinics in German
hospitals were contacted by the project leader (CH)
and informed about the study. All outpatient clinics
which were willing to participate have been included in
the study. Recruitment strategies will be individualised to
ensure that centres’ specific requirements are addressed
(please see screening visit). The feasibility of recruitment
is currently being tested in the pilot study.
Allocation
Clusters will be stratified by type of hospital (university
hospital or community based hospitals). Allocations will
be computer generated and will be performed by a
statistician not involved in the conduct of the trial.
Prior to randomisation of the centres, contextual factors
of the participating centres will be assessed in a baseline
survey.
Centres will be aware of their allocation status. To
minimise selection bias, patients will not receive explicit
information about their allocation group, but will
only be informed that they will be assigned to one of two
methods of information provision about MS immunother-
apy (information provision only or information provision
plus information by a nurse).
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Blinding of patients in patient information trials is difficult
as the intervention can be easily detected. Therefore, due
to the nature of the intervention it is not possible
that clusters and patients are blinded. Nevertheless,
contamination is avoided by the cluster design and
patients will only be informed that two different ways
of decision support regarding immunotherapy, information
provision only or information provision plus information
by a nurse, will be assessed. Assessment of the endpoints
will be evaluator blinded as persons concerned with
outcome assessment (by telephone interviews) will
not be informed about patient and centre allocation.
Data collection methods
Data will be collected at seven time points using
web-based questionnaires (see Table 1). Use of the
web platform will be explained via information sheets
and through personal information within the study
centres. Additionally, some data will be collected by
telephone using trained and blinded interviewers after
six months and, depending on funding, after 12 and
24 months (see Additional file 1).
Statistical methods
For the primary outcome measure, the proportion of
informed decisions within a treatment group, a generalised
linear mixed model, reflecting the hierarchical structure of
the data will be used [65]. Due to the relatively small
numbers of clusters, imbalances in baseline characteristics
on cluster and individual level may occur which are not
fully covered by randomisation. Therefore the model will
be adjusted for baseline variables. The treatment effect will
be analysed at cluster level, whereas covariates will be
analysed individually by the model. For the secondary
outcome measures linear mixed models or generalised
linear mixed methods will be used adjusting for clusters by
random effects. These models also allow analyses of sub-
groups. All analyses will be performed on the intention-to-
treat population.
It is planned to perform subgroup analysis of the two
groups of patients included in the trial: first, those with
a recent diagnosis, facing an initial decision on immuno-
therapy and second, those considering changing to an
oral treatment. Apart from demographic baseline data,
all analyses will be cluster-adjusted. We will report causes
for study withdrawal for each patient to clarify whether
there are any differences between the intervention and
control clusters.
In addition, a sensitivity analysis will be performed to
evaluate the robustness of study results and to explore
different imputation techniques. Altman [66] addressed
that there is no ideal method to address missing data.
Therefore, different common imputation techniques [67]will be applied and reported with as well as without
imputation techniques as suggested by Altman [66].
Last observation carried forward, as well as best and
worst case scenario for dichotomous outcomes and
multiple imputation techniques, will be conducted in
the sensitivity analysis [68].Harms
As relevant adverse events are unlikely, no interim
analyses are planned and no stopping rules will be
applied. Nevertheless, safety measures are applied as
tertiary endpoints to control for anxiety, depression,
and disease-specific quality of life. Furthermore, stand-
ard disease monitoring parameters will be collected
(such as relapse rate, disability status, and functional
status).Research ethics approval
Ethical approval has been obtained from the ethical
committee of Hamburg Chamber of Physicians (approval
number: PV4576), and has been obtained from local
committees at each centre location. Please see Additional
file 2 for details.Feasibility study and pilot trial
The intervention and the study procedures including
outcome assessment were pre-tested through a feasi-
bility study and are currently being tested in a subse-
quent pilot randomised controlled trial in the study
centres in Hamburg and Bochum. The pilot study
aims at first testing the randomisation procedure and
second to gather data on feasibility of conducting the
main trial.
For the feasibility study, four nurses specializing in
MS from the centres in Hamburg and Bochum have
received training in Hamburg. The feasibility study
has been conducted over six months and 12 patients
were included. Each decision coach has coached three
patients, chosen by either the decision coach or the
physician. The feasibility study aimed to evaluate the
training course, access the acceptability of the prog-
ramme (decision coaches, patients, and study sites),
and to detect barriers and facilitators. Therefore, tele-
phone interviews with included patients were conducted
and analysed.
Currently, a pilot randomised controlled trial is being
performed in the two centres in Hamburg and Bochum.
Here, we aim to recruit 30 patients per centre, following
the main study procedure with the following adaptation:
both intervention and control intervention will be tested
in each study centre. Therefore, both centres will receive
randomised days to recruit either for the IG or CG.
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hypothesis that the concept is feasible for decision
coaches and patients. In detail, it is tested whether:
1. patients agree on initially consulting a nurse
(decision coach),
2. the patient workbook is acceptable for patients and
decision coaches,
3. the DECIMS-Wiki is helpful in the decision process,
4. the patient workbook and information platform can
be used together during encounters,
5. study recruitment is feasible, and
6. outcome measurements are acceptable.
Data from the feasibility study have been used to adapt
the train-the-trainer course to nurses needs in the
encounters and we developed moderation cards (instead
of an information sheet) for the decision coaches. Further,
as a result of the pilot study, it has been decided to
videotape all coaching sessions.
In addition, different possibilities to present data of
risk communication (for example graph or pictogram)
will be evaluated in terms of knowledge and understanding
via web-based surveys in cooperation with the German MS
Self-help Society (DMSG). For example, an education tool
to support the comprehension of confidence intervals will
be tested.
Process evaluation
Process evaluations should generally be accompanying
complex intervention studies in order to measure
programme fidelity and explore reasons for an effective
or ineffective intervention [69]. Following the guidance
of the Medical Research Council, the cluster randomised
controlled trial will be accomplished by a process evaluation
in order to assess study processes concerning patients,
decision coaches, and the setting and context of the study.
A process evaluation is of great use to understand the
results of a study, and to later translate a successful
intervention into practice [41,70].
Recently, Grant et al. [70] have published guidance for
the development of process evaluations specifically
addressing process evaluations for cluster randomised
controlled trials of complex interventions. This frame-
work will be used to guide the process evaluation of
this study.
Ferlie and Shortell [71] suggest four levels of change
which have to be considered in order to reach quality
improvements in health care systems: individual level,
group or team level, overall organisation level, and larger
system level or environment in which individual organi-
sations are embedded. Thus, teams build an important
basis for changes. Depending on the level(s) and the
intervention targets, different theories are relevant [71].The intervention in this project targets people with MS,
who face a decision) concerning immunotherapy (begin,
start or change of immunotherapy). Therefore, MS
nurses who work in an outpatient clinic will be trained as
decision coaches. The study intervention affects all
persons who are involved in the decision-making process;
patients, physicians, and nurses. Presumably, a successful
intervention depends on the support and attitude of the
whole MS outpatient team towards the planned decision
coaching intervention. However, it is hypothesised that a
successful implementation of the intervention relies
decisively on the motivation and attitude of the trained
MS nurses.
The knowledge, which will be imparted during the
nurse training course, is based on the principles of
evidence-based medicine [72], and the knowledge trans-
fer reflects established educational theories and concepts
[73,74]. Further, the theory of planned behaviour [75]
has been applied concerning contents of the training
and the transfer of knowledge into practise (decision
coaching performance).
Overall, the project is guided and determined by the
principles of evidence-based medicine [72] and EBPI
[76]. Further guidelines and concepts are considered: the
MRC guidance for developing and evaluating complex
interventions [41] for the design of the study and the
SDM concept [46] to design and conduct the decision
coaching intervention.
As mentioned above, the process evaluation is a
mixed-methods study [77]. Qualitative and quantitative
methods will be applied in combination and will be
analysed together in order to illustrate and explore
changes related to the decision coaching intervention
on the cluster level (as for example change of structure in
the outpatient’s clinics), as well as the individual level (as
for example attitudes of the nurses). Partly, the quan-
titative results of the trial will be used to determine
questions of the qualitative interviews to be con-
ducted after the study. Therefore, quantitative and
qualitative methods are used intentionally to acquire
a comprehensive impression of study processes and
mechanisms.
In this process evaluation, a variation of the embedded
design of mixed-methods studies is applied [78]. Besides,
qualitative methods have been used within the feasibility
study before the start of the trial to investigate study
materials (the DECIMS-Wiki and patient workbook)
with regard to user-friendliness and comprehensibility
(see also trial protocol).
The framework proposed by Grant et al. [70] consists
of 10 domains (Figure 3). Three domains are comprised
of processes in which clusters are involved: recruitment of
clusters, delivery to clusters, and response of clusters.
Three domains address the processes within the target
Figure 3 Overview of the process evaluation steps (from Grant et al. [70]).
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to individuals, and response of individuals. Further chap-
ters cover theory, context, maintenance, and unintended
consequences (see Figure 3).
As shown in Figure 3, effectiveness is displayed
additionally to the 10 process evaluation steps. This
concerns the results of the trial, which for instance
determine the research questions of the qualitative
interviews with patients after the trial is finished.
The primary aim of this theory based process evaluation
is to explore underlying mechanisms and to determine
effect modifying factors. Following the framework, the
objectives are to:
1. explore the reaction of the clusters (such as the
delivery of the intervention, response to the training
course, and maintenance);
2. identify barriers and facilitators concerning the
delivery of the intervention (coaching) to the
patients;
3. assess cluster-specific differences (such as cluster
reach and organisational differences);
4. measure the reaction of individuals with respect to
responsiveness towards study recruitment and the
intervention;
5. identify barriers and facilitators of study
participation and of study retention;
6. ascertain structural problems;
7. analyse which study components work or do not,
and for which reason; and8. look for unintended consequences of the
intervention (decision coaches, patients, and
clusters).
Additional file 3 shows the application of the framework
to this study. In the following, the planned components
of the single domains are described in more detail.
Questionnaires, which will be used for this process
evaluation, have been developed by the research team
and were tailored to the intervention. The questionnaires
have been tested for usability. Nonetheless, published
work in this field has provided useful guidance for
the development of the questionnaires for nurses [79].
Most of the described content of this process evaluation
refers to the IG. Content which also refers to the CG is
marked (CG).
Context
Relevant factors of the German health system will be
described and their relevance for this project will be
discussed. A total of 14 different MS outpatient clinics
are involved in the study, nine related to university
hospitals and five to community based hospitals.
Depending on the location, there is significant variation
between the outpatient clinics, and due to factors such as
size, practice hours, and clinical focus of the clinics, the
number of potential study participants vary considerably.
In the planning phase of the study, participating centres
were visited in order to gain important information
about structure and processes within the outpatient
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the conduct of the study and process evaluation content
was adapted.
Patient populations of the different outpatients clinics
consist of patients who:
1. recently received a diagnosis and require
information about therapy options,
2. visit the outpatient clinic regularly and now face a
treatment decision (start, stop, or change of
immunotherapy),
3. seek a second opinion, and/or
4. other (for example acute relapse).
Accordingly, the staffing (doctors, study nurses, MS
nurses, and receptionists) and the roles of outpatient
clinics in the respective neurological department are
organised differently. Similarly, the clinics differ in terms
of everyday processes, the functions assumed (by doctors
and nurses) in patient care, and patient populations.
Many of these differences have been noticed during
the visits. As a result, the analyses of these different
contextual conditions will provide important informa-
tion concerning transferability of the concept to MS
outpatient clinics in Germany, and to other countries
and medical fields.
Prior to randomisation of the centres, study contextual
factors will be assessed in a baseline survey (self-developed
questionnaire (for both the IG and CG)). In addition, cer-
tain aspects of possible centre-specific effects (promoting
factors and barriers) will be explored in more detail after
completion of the study through qualitative interviews.
For example, the possible advantages and disadvantages of
the team structure (such as number and qualification of
employees) for the work of decision coaches will be
studied by qualitative interviews.
Recruitment of clusters
Clusters consist of participating MS outpatient clinics
(see above). Within the collection of baseline data, it is
planned to ask the physicians and nurses within the
centres why they are participating in the study. Centres
that withdraw participation will be asked for the reason.
Delivery to clusters
The decision coach training, which one or two MS
nurses from all intervention clusters will receive, has
been developed and will be performed by the study
working group in Hamburg. In order to better understand
and interpret modes of action of the complex intervention,
a feasibility study, followed by an ongoing pilot study, was
performed. Based on the results of these studies, both the
training of nurses and the intervention (coaching sessions
and supplementary materials) have been revised.The intervention leads to changes in common practice
within intervention clusters. On the one hand, MS nurses
get involved in a new or expanded field of activity and
acquire the relevant skills for this through the decision
coach training. In addition, the local structure in MS
outpatient clinics is changed due to the implementation of
the coaching concept.
As part of the process evaluation it is determined to
which extent clusters have received the intervention.
The focus of the observation is to evaluate whether the
intervention has been conveyed to all clusters in the
same way. For this purpose, it is documented whether
all participating nurses attend all training lectures,
including subsequent training activities. Important
aspects related to the training are assessed at the end of
the training using questionnaires covering, for example,
satisfaction and understanding. A knowledge assessment
on relevant training content is performed before and after
the training.
Further, it will be measured whether the course of the
study (for example recruitment) has been communicated
to all outpatient clinics (intervention and control clusters).
Moreover, it will be captured whether physicians have
received the SDM information, and if at least all principal
investigators participated in the web-based meeting where
the initiation of the DECIMS trial at the centre was
performed (for both the IG and CG).
Response of cluster
An important part of the process evaluation is the
attitudes of stakeholders (doctors and nurses) about the
intervention and related structural changes. Quantitative
surveys will be conducted at two time points (outpatient
clinic teams in the intervention and control clusters) and
at five time points (decision coaches: baseline, after
training, after six weeks, six months, and after study
completion) to determine changes in the course of the
study (see Additional file 4).
In addition, physicians and nurses in the intervention
clusters are interviewed after study completion to determine
whether attitudes have changed during the course of the
study and, if so, what factors have led to these change.
Interviews will be semi-structured [80] and are subse-
quently evaluated by content analysis [81].
Further, it will be evaluated whether there are any
changes in the professional relationship between nurses
and physicians due to the intervention. Besides possible
changes in the professional relationship between physi-
cians and nurses, changes in the physician-patient com-
munication will be addressed. Therefore, in four centres
10 physician-patient encounters will be audiotaped and
analysed concerning SDM content (MAPPIN’SDM).
An important aspect is the implementation of the inter-
vention in different centres and to determine characteristics
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(barriers and facilitators). For example, the number of
patients within centres or the qualification of the
MS-nurse might be important factors here.
Apart from interviews with decision coaches, facilitators
and barriers of standardised implementation of the decision
coaching will be assessed through a nurse logbook for each
patient. In this web-based logbook, nurses record important
information about patients and coaching appointments,
such as duration or discussed SDM steps.
Following the training, the decision coaches perform
training coaching sessions with two patients, recorded
on video. As mentioned above, these first coaching sessions
are evaluated and nurses receive telephone feedback after
every patient by AR, together with a psychologist.
Willingness of nurses to work and further train in
the new action field, use of the distributed materials
(moderation cards and patient workbook), use of the
DECIMS-Wiki, and gathering information beyond the
provided information are also an important part of
the process evaluation and will be assessed through
logbooks, questionnaires, and qualitative interviews
after study completion.
Some evaluation questions are based on the theory of
planned behaviour [75] and aim to determine factors for
a good immunotherapy coaching. Good immunotherapy
coaching, as defined in the study, is provided when all six
SDM steps have been addressed. Therefore, all coaching
sessions will be videotaped and we aim to analyse the
videos of at least 50 randomly chosen patients (dyadic
MAPPIN’SDM evaluation [59]). Upon completion of the
study, questions which arise from the video analysis and
quantitative evaluation are addressed through qualitative
interviews. In addition, it will be assessed by questionnaires
whether and to what extent the intervention has had an
impact on nurses in the intervention clusters who did not
receive the training. In the following, a selection of aspects
that will be covered is listed for the physicians of the IG:
1. attitude towards the intervention,
2. distress through additional organisational effort,
3. reduction of workload due to nurses’ counselling,
4. handing over responsibility to nurses,
5. change in patient communication, and
6. change in communication with nurses.
A selection of aspects that will be covered is listed for
the decision coaches of the IG:
1. attitude towards the intervention and personal interest,
2. higher workload versus work routine,
3. changes in the inter-professional relationship to the
physicians and others, and
4. facilitating factors and barriers.Recruitment and reach in individuals
To ensure a standardised recruitment, the recruitment
procedure was determined after most of the participating
centres had been visited by members of the research team.
A non-responder analysis will be conducted in all centres.
On the one hand it should be ascertained whether
there are fundamental differences between control
and intervention centres. On the other hand it should
be determined if there are considerable variations in the
reasons for or against study participation in individ-
uals. Therefore, patients will be briefly asked for their
reason/s not to take part in the study (screening form
two). Moreover, reasons for taking part in the trial
will be surveyed.
Delivery to individuals (dose delivered)
As aforementioned, all coaching sessions will be video-
taped and analysed. The analysis focuses the assessment of
coaching quality on respective SDM content Here, patient
information about benefits and harms of therapy options,
using the DECIMS-Wiki, are of particular relevance. In
addition, nurses document in the logbooks which SDM
steps have been discussed during the coaching session,
how many coaching sessions have been performed, and
duration of sessions. Patients are asked to fill in a short
questionnaire directly after the last physician encounter.
The questionnaire assesses, among other things, the use of
and satisfaction with the DECIMS-Wiki, especially
focussing on nurses as a possible influencing factor. For
instance, the attitude of the nurse towards the interven-
tion could have an impact on coaching performance.
After study completion, three patients per IG centre
(purposeful sampling) will be questioned, using semi-
standardised interviews, in order to determine which
aspects of the intervention were helpful for the patient in
the decision-making process, and where any action or
change was needed. The interview guide will be created
based on the analysis of the questionnaires. Depending on
resources, use of the DECIMS-Wiki will be evaluated
in the CG.
Response of individuals (dose received)
Apart from monitoring the transmission of the interven-
tion, patients’ responses will be investigated, focussing on:
1. changes in risk knowledge (using the risk knowledge
questionnaire [53], for both the IG and CG);
2. satisfaction with the intervention (for both the IG
and CG);
3. changes in patients’ attitudes (for example concerning
immunotherapy; for both the IG and CG);
4. structural barriers or barriers with regard to
content, which hinder patients to actively participate
in decision-making;
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6. influence of coaching on patient-physician
communication.
Questionnaires (with some open questions; for both
the IG and CG), videos of consultations (IG), and in-
terviews (for both the IG and CG) and/or focus groups
(for both the IG and CG) will be used for the evalu-
ation. Some aspects are already covered by primary
and secondary endpoint questionnaires. Subgroup ana-
lyses are intended to determine whether coaching of
patients seeking a change of immunotherapy has a
greater or smaller effect compared to treatment-naïve
patients.Maintenance
The collection of possible behavioural changes in decision
coaches can provide important information to explore
which factors serve to maintain the implementation of the
intervention or have a limiting influence. The following
aspects will be covered for decision coaches:
1. DECIMS-Wiki-use as a potential factor,
2. change of DECIMS-Wiki use in the course of the
study,
3. self-assessed changes in knowledge and skills
(for example coaching skills) during the study,
4. use of the materials (moderation cards and patient
workbook),
5. willingness to work and train in the new field of
activity,
6. self-assessed change in attitude of nurses in
the course of the study (for example, in terms
of coaching and about immunotherapies
(see also nurses and response of cluster)).
The following aspects will be covered for patients:
1. factors that lead to reconsidering the decision for or
against immunotherapy (for both the IG and CG),
2. DECIMS-Wiki use as a potential factor (for both the
IG and CG), and
3. contact with the decision coach after the coaching
session(s) (IG).Unintended consequences
Patients
Potentially, negative as well as positive effects may be
caused by the intervention. Therefore, security parameters
(HADS [61] and HAQUAMS [62]) are applied to assess
positive and negative changes in patients. In addition,
other possible effects of the intervention will be identified
on the basis of interviews and questionnaires.Decision coaches
It will be assessed (by questionnaires and interviews)
whether the training or coaching evokes unintended
consequences such as anxiety, burden within the situation,
and/or a conflict between their beliefs or current practice
in the outpatient clinics and the content of the interven-
tion, in trained nurses.
Physicians (intervention group)
Possible effects of the intervention on the relationship
between physicians and patients and physicians and
trained nurses will be evaluated via questionnaires and
interviews.
Theory
The Theory of Planned Behaviour (TPB) is based on the
assumption that behaviour is largely the result of setting,
beliefs, and expectations regarding future events. When
weighing different alternatives, an individual will choose
the action that most likely causes a positive result.
According to the theory of planned behaviour, the
domains ‘attitude’, ‘subjective norm’, and ‘perceived
behavioural control’ determine the behaviour of a
person. In a previous project, a questionnaire based on
the theory has been developed in order to elaborate the
intended behaviour respective to a decision of patients
with MS on immunotherapy [57]. This is one of the
questionnaires used in the trial.
Beyond that, the development of the training programme
for nurses was guided by the theory of planned behaviour,
and the theory will be considered and used in the develop-
ment of the process evaluation questionnaires to identify
barriers and supporting factors. Beyond the TPB as on
underlying framework of this project, the concepts of
SDM, evidence-based medicine, and EBPI have contributed
significantly to the development and the contents of the
intervention [46,75].
Data analysis (process evaluation)
As described by Creswell and Plano Clark [78], the main
steps for the data analysis in the embedded mixed-methods
design are:
1. analysis of the primary data set (trial data, see
Table 1),
2. analysis of the secondary data (process data),
3. specification of dimensions by which the results
should be compared,
4. specification of what information from dimensions
should be compared,
5. comparison of data sources, and
6. data interpretation according to the research
questions (in which way do secondary data sets
contradict, augment, or support trial results?).
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lysed separately. After that, the data will be connected
and the results will determine the interview questions.
Finally, all data sets will be merged (joint display).
The trial endpoint data analysis will be performed
according to the protocol. Quantitative process evaluation
data (surveys and evaluation forms) will be analysed
descriptively using SPSS (International Business Machines
Corporation (IBM), Armonk, United States of America) or
R (R Development Core Team) software. Some subgroup
analyses will be performed (for example, regarding the start
or change of immunotherapy and decision type) in order to
explore the impact of the intervention on different groups.
Interviews will be analysed by content analysis [81] and
coded thematically with a specific software programme
(QCAmap (P. Mayring and T. Fenzl), Klagenfurt, Germany)
Qualitative data analysis will be guided by the TPB.
Summary process evaluation
The framework of Grant et al. [70] facilitates systematic-
ally retrieving, appraising, and analysing important
aspects of the complex intervention of decision coach-
ing. The planned questionnaires allow for an elaborate
interpretation of study results. In addition, the qualita-
tive interviews enable further exploration of facilitators
and barriers concerning the implementation of the inter-
vention in different centres with different structures and
processes, as well as different groups of people. The
process evaluation offers the opportunity to capture the
way in which the complex intervention causes effects,
and to determine factors that have a supporting or
hindering influence. Intentionally, besides some open
questions in the evaluation forms, no qualitative data
is collected during the trial, so as not to interfere
with the processes of the complex intervention. However,
important potential problems can be detected by regular
telephone calls with the nurses of all centres. Through
qualitative interviews and possibly focus groups after the
trial, it is possible to further elaborate on the results of the
quantitative questionnaires. Due to the interpretation
of the data, new questions may be raised that can be
addressed in the interviews. All quantitative questionnaires
of the process evaluation were specified and created before
the beginning of the trial. The qualitative interview guides
are created after the completion of the study, in order to
respond with flexibility, for example to unexpected events.
Discussion
The proposed cluster randomised controlled trial aims
to assess the effectiveness of a new model of patient
decision support concerning MS immunotherapy options
in Germany. As this intervention is associated with sub-
stantial structural changes, as for example nurses in
Germany seldom explain treatment options, the trial isaccompanied by a thoroughly developed mixed-methods
research process evaluation in order to explore the under-
lying processes.
This is the first cluster randomised controlled trial
where a nurse-led immunotherapy decision coaching
intervention in persons with RRMS is evaluated. This
study responds to Stacey et al.’s [16] call for more research
to evaluate the value of decision coaching beyond patient
decision aids.
In conclusion, this trial will investigate whether patients
with MS who are facing an immunotherapy treatment
decision will benefit from decision coaching delivered by
trained nurses.Trial status
Patient recruitment for the trial started in autumn 2014.Additional files
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